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Abstract 12 
As the scope of modern genomics technologies increases, so does the need for informative chemical 13 
tools to study functional biology. Activity-based probes (ABPs) provide a powerful suite of reagents to 14 
probe the biochemistry of living organisms. These probes, featuring a specificity motif, a reactive 15 
chemical group and a reporter tag, are opening-up large swathes of protein chemistry to investigation 16 
in vitro, as well as in cellular extracts, cells and living organisms in vivo. Glycoside hydrolases, by virtue 17 
of their prominent biological and applied roles, provide a broad canvas on which ABPs may illustrate 18 
their functions. Here we provide an overview of glycosidase ABP mechanisms, and review recent ABP 19 
work in the glycoside hydrolase field, encompassing their use in medical diagnosis, their application 20 
for generating chemical genetic disease models, their fine-tuning through conformational and 21 
reactivity insight, their use for high-throughput inhibitor discovery, and their deployment for enzyme 22 
discovery and dynamic characterization.  23 
Highlights 24 
x Glycosidases carry out many essential functions across all domains of life 25 
x Activity-based probes can interrogate complex biological samples for glycosidase activity 26 
x Glycosidase probes can characterize enzymes of biomedical/biotechnological interest 27 
x Analysis of conformational itineraries may inform the design of future probes. 28 
x Activity-based probes assist high-throughput discovery of inhibitors 29 
 30 
1. Introduction and History 31 
The development of modern genomic technologies has provided us with the ability to sequence (and 32 
even edit) the genetic code of essentially any organism. However, our understanding of how this 33 
wealth of genetic information links to biological function in vivo is still limited. The majority of the 34 
biochemical reactions that underpin life are catalyzed by protein enzymes, whose primary sequences 35 
are encoded by genes, but whose functions are often difficult to deconvolute from the genetic code. 36 
Enzyme structures and functions are hard to predict from primary sequence alone, and their activities 37 
may be further modulated by post-translational modifications, processing, intermolecular interactions 38 
and subcellular localization.  39 
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Activity-based protein profiling (ABPP) has gained prominence as a powerful tool for the functional 1 
annotation of enzymes within complex biological milieu. ABPP relies on the availability of suitable 2 
activity-based probes (ABPs) that react with broad classes of enzymes, allowing investigation of their 3 
identity and functions. ABPs are typically comprised of 3 main components: 1) a specificity endowing 4 
motif that directs the ABP towards a particular group of enzymes through key-interactions to the 5 
enzyme active-site, 2) a ĐŚĞŵŝĐĂů  ‘ǁĂƌŚĞĂĚ ? ƚŚĂƚ ƌĞĂĐƚƐ  ?often irreversibly) with catalytic residues 6 
within the active-site, 3) a reporter group that enables detection and/or capture of the ABP after 7 
reaction with the enzyme (Figure 1a). 8 
ABPs are intimately linked with the concept of mechanism-based inhibitors. The first ABPs were 9 
derived from linking mechanism-based inhibitors of particular enzyme classes to reporter moieties 10 
that could be exploited for analysis. Early work by Mason et al. showed that cathepsin B and L specific 11 
ABPs could be developed by simple modification of existing inhibitors to incorporate a 125I 12 
radioisotope[1] ?dƵŶŝŶŐƚŚĞ ‘ƉĞƉƚŝĚĞ ?ƐĞƋƵĞŶĐĞŽĨƚŚĞƐĞWƐĞŶĂďůĞĚtargeting of different classes of 13 
proteases, such as the profiling of proteasomal E-subunits by 125I-nitrophenyl-(Leu)3-vinylsulfone as 14 
demonstrated by Bogyo, Ploegh and coworkers[2]. This strategy of converting inhibitor to ABP was 15 
also used by Cravatt and coworkers in their seminal 1999 report, showing that reactive 16 
fluorophosphonates could be derivatized to produce broad spectrum serine hydrolase ABPs, with a 17 
biotin reporter group allowing for detection by peroxidase conjugated avidin[3]. 18 
ABPs have now been developed for many enzyme classes, including methyltransferases[4], kinases[5], 19 
phosphatases[6], ubiquitin ligases[7], and glycosidases[8-11] (Figure 1b). This review summarizes 20 
recent work in the development of glycosidase targeting ABPs, with some comments regarding 21 
possible future directions for the field. For a more historical perspective, the reader is invited to 22 
consult the comprehensive review of Rempel and Withers[12], and references therein.   23 
2. ABPs for glycoside hydrolases 24 
Carbohydrate containing biomolecules (oligosaccharides, polysaccharides, small and macro- 25 
molecular glycoconjugates) play important metabolic, signaling and structural roles across all domains 26 
of life. Glycoside hydrolases (GHs; also known as glycosidases) are a major class of enzymes 27 
responsible for hydrolytic breakdown of carbohydrates, and are essential for diverse biological 28 
processes. ABPP of glycosidases can provide insights into the role these enzymes play in complex 29 
biological systems, as well as enabling the identification of previously unknown glycosidases.  30 
Mechanistically, glycosidases are classified as inverting or retaining, depending on whether the 31 
enzymatic reaction proceeds with net inversion or retention of stereochemistry at the cleaved 32 
glycoside anomeric center[13]. Inverting glycosidases typically catalyze hydrolysis via a single step 33 
nucleophilic displacement at the substrate anomeric center. In contrast, most retaining glycosidases 34 
utilize a two-step mechanism mediated by two key catalytic residues: a nucleophile and a general 35 
acid/base, and proceed via a covalent glycosyl-enzyme intermediate (Figure 2a). Trapping this 36 
covalent intermediate is the conceptual basis for most mechanism-based inhibitors and ABPs that 37 
target retaining glycosidases.  38 
2.1. Glycosidase ABPs that stabilize the covalent intermediate lifetime 39 
A major group of retaining glycosidase mechanism-based inhibitors function by extending the lifetime 40 
of the covalent  ‘glycosyl ?-enzyme intermediate, which can be achieved using activated fluorosugar[14-41 
16] (Figure 2b) or carbasugar[17] based molecules. In their seminal work, Vocadlo and Bertozzi 42 
reported the use of 6-azido-2,6-dideoxy-2-fluoro-E-D-galactosyl fluoride ABPs to label E-43 
galactosidases in crude cell lysates. The modified enzymes were detected by means of Staudinger 44 
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ligation to a phosphine-FLAG tag, followed by immunoblot[9]. Fluorosugar based ABPs have since 1 
been synthesized for the labeling of E-glucosaminidases[18], E-xylanases[19,20] and acid E-2 
glucocerebrosidase (GBA)[21]. Although fluorosugars work well against many glycosidase classes, they 3 
are rapidly turned over in some cases (e.g. 2-deoxy-2-fluoro-D-D-glucosides by D-glucosidases)[15], 4 
precluding the use of these compounds as general probes for all retaining glycosidases. 5 
Cyclopropyl and vinyl carbasugar inhibitors operate in a conceptually similar manner to fluorosugars, 6 
by forming a stable  ‘ŐůǇĐŽƐǇů ? ŝŶƚĞƌŵĞĚŝĂƚĞ that accumulates on enzyme[22]. However, these 7 
molecules also suffer from similar drawbacks to fluorosugars, being turned over too rapidly in some 8 
cases to be of use as probes. To ameliorate problems of rapid turnover, fluorosugar and carbasugar 9 
moieties can be combined. Thus cyclopropyl and vinyl 2-deoxy-2-ŇƵŽƌŽ-carbagalactose inhibitors have 10 
been observed to form longer lived D-galactosidase-conjugates compared to both their 2-deoxy-2-11 
fluoro-galactose and carbagalactose congeners[23,24].     12 
2.2. Electrophilic glycosidase ABPs 13 
Cyclitol epoxides, such as conduritol Bepoxide (CBE; Figure 2c), employ an electrophilic trap 14 
mechanism to label their target. Pioneering work by Legler in the 1960s provided a possible route into 15 
glycosidase ABPs through the use of 14C radiolabeled CBE[25,26]. However, the intrinsic promiscuity 16 
of CBE (partially related to its internal symmetry) renders it a poor tool for the study of glycosidase 17 
and cellular biology. A marked improvement on CBE was realized with the discovery of the natural 18 
product cyclophellitol. First isolated from Phellinus sp[27], cyclophellitol resembles E-D-glucose in 19 
configuration, but with a highly electrophilic epoxide instead of an aglycone. Engagement of 20 
cyclophellitol by retaining E-glucosidases results in attack of the epoxide by the E-glucosidase catalytic 21 
nucleophile, leading to irreversible alkylation of this residue[28] (Figure 2c).  22 
Since its discovery, multiple synthetic routes towards cyclophellitol have been reported[29], however 23 
these typically required multi-step synthetic transformations and expensive starting materials. The 24 
facile synthesis of cyclophellitol from D-xylose by Madsen and coworkers in 2005 paved the way for 25 
exploitation of this scaffold for the development of ABPs[30]. In 2010 Witte et al. reported the first 26 
cyclophellitol derived ABPs, in which a reporter group was appended to the C6 position of the 27 
cyclophellitol  ‘ŐůƵĐŽƐŝĚŝĐ ?ƌŝŶŐ[10]. This produced highly potent (nanomolar KI) and selective ABPs for 28 
lysosomal glucocerebrosidase (GBA), enabling detection of this enzyme in lysates from various 29 
biological samples. Although useful for investigating GBA activity, the bulky C6 substituent of first 30 
generation cyclophellitol-derived ABPs precluded their activity against other retaining E-glucosidases. 31 
This was addressed by the development of N-acylated and N-alkylated cyclophellitol aziridines, in 32 
which the reporter moiety is projected towards the direction normally occupied by the substrate 33 
aglycon, leading to broad spectrum ABPs that label all retaining E-glucosidases[31]. Modulation of 34 
ƐƵďƐƚŝƚƵƚŝŽŶĂŶĚƐƚĞƌĞŽĐŚĞŵŝƐƚƌǇĂƌŽƵŶĚƚŚĞ ‘ŐůǇĐŽƐŝĚŝĐ ?ƌŝŶŐŽĨƚŚĞĐǇĐůŽƉŚĞůůŝƚŽůƐĐĂĨĨŽůd has now 35 
provided ABPs for a wide range of different retaining glycosidases[32-35].  36 
Haloketone (typically bromoketone) glycosides are another example of electrophilic glycosidase ABP, 37 
which inhibit retaining glycosidases via alkylation of nucleophilic residues within the enzyme active 38 
site (Figure 2d). C-bromoketone glycosides and N ?ďƌŽŵŽĂĐĞƚǇů-glycosylamines have been developed 39 
for the inhibition of E-glucosidases, E-glucanases[36], and endo-xyloglucanases[37]. Although there 40 
are relatively few reports of ABPs based upon haloketone type inhibitors, Keresztessy et al. reported 41 
the use of 14C radiolabeled N ?ďƌŽŵŽĂĐĞƚǇů-E-D-glucosylamine to identify the catalytic acid/base 42 
residue of cyanogenic E-glucosidase (linamarase) from Manihot esculenta Crantz (cassava)[8]. 43 
Anderson et al. also reported the use of an azido N-iodoacetyl-glycosylamine probe to profile secreted 44 
cellulolytic enzymes of several Trichoderma reesei strains[38]. It should be noted that whilst there 45 
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seems no obvious reason why haloketone glycosides should not also label inverting glycosidases, to 1 
our knowledge only inhibition of retaining glycosidases has been observed to date.  2 
2.3. Glycosidase ABPs that generate reactive intermediates in situ 3 
Photoactivatable affinity-based probes (AfBPs) have been explored as potential tools for glycosidase 4 
profiling (Figure 2e). A 1992 study by Kuhn et al showed that thioglycosides functionalized with a 5 
photoactive diazirine moiety could label the active site of human lysosomal Ehexosaminidase A[39]. 6 
Similarly, Orth et al demonstrated that benzophenone containing GlcNAc configured AfBPs label the 7 
active site of recombinant bacterial N-acetylglucosaminidase NagZ[40]. Gandy et al utilized a suite of 8 
iminosugars functionalized with photoactivatable aromatic azides to profile both recombinant 9 
glycosidases and glycosidases in crude E. coli lysates[41]. Notably, the authors of this study reported 10 
labeling of both retaining and inverting glycosidases by their probes. 11 
One general  ‘disadvantage ? of photoactive AfBP profiling is that these molecules do not only target 12 
enzymes, but can in principle label any carbohydrate binding protein of appropriate specificity, as 13 
demonstrated by the labeling of a GM2-activator protein by a ganglioside based diazirine AfBP[42]. 14 
Furthermore, photoactivation of probes in free solution can contribute to off target labeling of even 15 
non-carbohydrate binding proteins.  A true ABP based strategy for labeling glycosidases has been to 16 
employ probes that only release a reactive group upon enzymatic attack, which can then proceed to 17 
label nearby residues around the enzyme active site. The glycosylmethyltriazines pioneered by Sinnott 18 
and coworkers are early examples in this class[43], which fragment upon enzyme mediated 19 
protonation to form a reactive carbocation that alkylates nearby nucleophilic amino acid sidechains. 20 
However, glycosylmethyltriazines are prone to non-enzymatic degradation at acidic pHs, making the 21 
study of glycosidases (which typically require acidic pH for optimal activity) using these molecules 22 
problematic.  23 
Quinone methide based molecules are now predominant amongst the class of reactive group 24 
generating ABPs, and have been used to study glycosidases in both biomedical and biotechnological 25 
contexts[44-46] (Figure 2f). Although useful against both retaining and inverting glycosidases, the use 26 
of quinone methide ABPs can also lead to unspecific protein labeling, due to diffusion of activated 27 
quinone methide electrophiles out of the enzyme active sites of their initial formation. Such off-target 28 
labeling suggests that quinone methide ABPs are better suited for broad labeling of macromolecular 29 
complexes or cellular structures[11,44,45], rather than precision labeling of individual glycosidases.  30 
3. Glycosidase conformational itineraries and ABP reactivity 31 
One of the defining features of glycosidase mediated substrate cleavage is the complex series of 32 
conformational distortions undergone by the substrate glycone ring during the catalytic cycle. These 33 
distortions are necessary to accommodate the oxocarbenium ion-like transition state of glycoside 34 
hydrolysis, in which at least 4 atoms of the glycoside ring (including the endocyclic oxygen) must be 35 
coplanar[47]. The sequence of conformational distortions employed by a glycosidase to process its 36 
substrates is known as the conformational itinerary. These itineraries are typically conserved between 37 
related glycosidase families (Figure 3a).  38 
Recent years have seen an increasing use of conformational free energy landscape (FEL) analysis as a 39 
tool to predict the conformational itineraries employed by different glycosidases[47]. FELs can also be 40 
used to calculate conformations favored by glycosidase ABPs and mechanism-based inhibitors, which 41 
can shed light on differences in labeling efficiency between different classes of glycosidase ABPs, and 42 
inform the design of new probes with improved potency and/or specificity. FEL analysis of 43 
cyclophellitol-derived inhibitors/ABPs has shown that these molecules typically adopt a 4H3 half-chair 44 
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ground state conformation, due to the stereochemical constraints placed on the cyclitol ring by the 1 
strained epoxide/aziridine moiety[48]. Significantly, many families of retaining glycosidases process 2 
their substrates via a 4H3 transition state complex[47], and thus cyclophellitol-derived ABPs act as 3 
transition state mimics for these enzymes, typically showing low PM to nM equilibrium constants for 4 
initial binding (KI = ~15 PM for cyclophellitol against the TmGH1 E-glucosidase from Thermotoga 5 
maritima)[28]. Indeed, even neutral non-electrophilic carba-cyclophellitols, containing a cyclopropyl 6 
in place of the epoxide, are competent reversible glycosidase inhibitors due to conformational 7 
mimicry (Figure 3b)[48].  8 
The Michaelis complex conformation, adopted by substrates upon initial enzyme binding, can also be 9 
exploited for the design of mechanism-based glycosidase inhibitors. Cyclophellitol cyclosulfate 10 
inhibitors were designed based on this principle, with the first (glucose configured) inhibitors of this 11 
class showing exquisite selectivity for inhibition of D-glucosidases compared to E-glucosidases. The 12 
ground state conformation of cyclophellitol cyclosulfates is a 4C1 chair, which closely resembles the 13 
Michaelis complex conformation utilized by D-glucosidases, but not the 1S3 Michaelis complex 14 
conformation utilized by E-glucosidases. Thus D-cyclophellitol cyclosulfates rapidly inactivate D-15 
glucosidases, whilst their E-configured congeners are only marginal E-glucosidase inhibitors[49] 16 
(Figure 3c).  17 
Interestingly, mechanism-based inhibitors/probes that employ non-native conformational itineraries 18 
are well tolerated by some glycosidases. The D-D-galacto configured cyclopropane-carbasugars 19 
pioneered by Bennet and coworkers adopt an unusual 2H3 Michaelis complex conformation in the 20 
active site of D-galactosidases, owing to conformational restriction across the C5 ?O5 equivalent bond 21 
(the O5 position being occupied by a tertiary carbon in these molecules)[24]. Despite their non-native 22 
Michaelis conformation, these molecules react efficiently with GH36 D-galactosidases, although their 23 
ability to label GH27 D-galactosidases is more limited[17]. Taken together, it appears that mechanism-24 
based inhibitors employing non-native conformational itineraries can selectively target some classes 25 
of glycosidases, hinting at a strategy for the development of family specific inhibitors/probes.   26 
4. Recent developments in the glycosidase ABP field  27 
4.1. Glycosidase ABPP for biomedical diagnostics 28 
Several pathophysiological states, including mucopolysaccharoidoses and various lysosomal storage 29 
diseases (LSDs), arise from insufficient levels of glycosidase activity. Diagnosis of these conditions 30 
typically involves the use of activity assays to determine residual glycosidase activities in patient 31 
tissues. Such assays can be non-trivial, with specific conditions or inhibitors required to deconvolute 32 
activity of the enzyme of interest from overlapping enzymes in the tissue. ABPP is uniquely suited to 33 
address this challenge, and ABPs against various classes of glycosidases have demonstrated promise 34 
as possible diagnostic tools (Figure 4a). 35 
GBA is perhaps the most well-studied glycosidase from an ABPP-centric perspective; GBA deficiency 36 
is the causal driver of 'ĂƵĐŚĞƌ ?Ɛ ĚŝƐĞĂƐĞ ?caused by abnormal buildup of the GBA substrate 37 
gluĐŽƐǇůĐĞƌĂŵŝĚĞ ŝŶ ĐĞůůƐ ? ^ǇŵƉƚŽŵƐ ŽĨ 'ĂƵĐŚĞƌ ?Ɛ ĚŝƐĞĂƐĞŝŶĐůƵĚĞ thrombocytopenia, 38 
hepatosplenomegaly, and osteoporosis, with the type II variant also involving severe neuropathy with 39 
patients typically succumbing in infancy. ABPP using cyclophellitol-derived probes allows for rapid 40 
evaluation GBA activity in patient tissues, and can identify ' ĚĞĨŝĐŝĞŶĐǇ ŝŶ 'ĂƵĐŚĞƌ ?Ɛ ĚŝƐĞĂƐĞ41 
samples with sensitivity comparable to immunoblotting (a considerably more laborious 42 
technique)[10]. Use of suitably configured ABPs has also demonstrated that lysosomal D-glucosidase, 43 
lysosomal E-galactocerebrosidase, and lysosomal D-galactosidase are all amenable to ABPP profiling, 44 
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opening up avenues for the rapid diagnosis of Pompe[34], Krabbe[50] and Fabry[32] diseases 1 
respectively. Interestingly, the irreversible inhibitory nature of many ABPs can also be used to 2 
ĐŚĞŵŝĐĂůůǇ  ‘ŬŶŽĐŬ ŽƵƚ ? ĞŶǌǇŵĞ ĂĐƚŝǀŝƚǇ in vivo. Zebrafish treated with selective cyclophellitol 3 
derivatives accumulate glucosylsphingosine (derived from acid ceramidase mediated conversion of 4 
glucosylceramide), indicating  ‘ŬŶŽĐŬŽƵƚ ?ŽĨ'ĂĐƚŝǀŝƚǇĂŶĚ ƌĞĐĂƉŝƚƵůĂƚŝŽŶŽĨĂ'ĂƵĐŚĞƌ ?ƐĚŝƐĞĂƐĞ5 
phenotype[51]. 6 
Glycosidase overexpression can also be linked to pathophysiologies. Heparanase is an endo-E-7 
glucuronidase principally responsible for heparan sulfate (HS) breakdown in the body. Aberrant HPSE 8 
overexpression results in excessive HS degradation within the extracellular matrix surrounding cells, 9 
and releases of growth factors stored by extracellular HS networks. These factors increase cell motility 10 
and growth, and thus heparanase drives metastasis in a wide range of cancers. E-D-glucuronide 11 
configured cyclophellitol-derived ABPs detect heparanase in human tissue lysates, and may be useful 12 
diagnostic tools to track aberrant heparanase upregulation during cancer development[35].  13 
4.2. Glycosidase ABPP for imaging applications   14 
Many glycosidase ABPs are cell permeable, allowing for their use in cells, tissues, and even whole 15 
organisms, enabling a variety of imaging applications (Figure 4a). van Smeden et al have shown that 16 
epidermal GBA in intact skin sections can be visualized by confocal microscopy following application 17 
of fluorescent cyclophellitol-derived ABPs[52]. Similar GBA imaging in human fibroblasts was 18 
demonstrated by van Meel et al, who also applied correlated light and electron microscopy (CLEM) to 19 
confirm specific staining of the lysosomal compartment[53].  20 
In situ imaging to visualize cellular uptake and trafficking may be a useful technique to assess the 21 
efficacy of therapeutic enzyme uptake following enzyme replacement therapy regimens. Phenix et al. 22 
demonstrated that 18F-fluorosugar pre-labeled recombinant GBA could be tracked in mice by PET 23 
imaging, allowing for the uptake of GBA into organs following enzyme administration to be 24 
quantitated[21]. Higher resolution imaging of enzyme trafficking into cellular organelles has also been 25 
reported, albeit in cell culture systems. van Meel et al. used CLEM to visualize lysosomal accumulation 26 
of recombinant ABP pre-labeled GBA by human fibroblasts following its addition into culture media. 27 
The authors found that lysosomal accumulation of recombinant GBA occurred even in the absence of 28 
LIMP-II (the protein responsible for lysosomal trafficking of endogenous GBA) suggesting that 29 
lysosomal trafficking of recombinant GBA is a LIMP-II independent process[53]. Similarly, Artola et al. 30 
tracked ABP pre-labeled D-L-iduronidase (IDUA) uptake by mucopolysaccharidosis (MPD)I and 31 
mucolipidosis II (MD)II fibroblasts. In this case, application of mannose-6-phosphate abrogated uptake 32 
of recombinant IDUA, confirming that IDUA uptake was dependant on the mannose-6-phosphate 33 
pathway[54].  34 
4.3. Glycosidase ABPP for inhibitor discovery  35 
Fluorescent glycosidase ABPs can be exploited to screen for inhibitors in compound libraries through 36 
the use of the high-throughput fluorescence polarization (FluoPol) assay format. When excited with 37 
plane polarized light, enzyme bound fluorescent ABPs will retain a greater degree of polarization in 38 
their emitted light compared to free ABPs in solution. Thus, incubation of enzyme-ABP mixtures with 39 
compounds that reduce ABP binding will lead to reduced fluorescence polarization (Figure 4b). Lahav 40 
et al. used cyclophellitol aziridine equipped with a TAMRA-fluorophore in a FluoPol assay to identify 41 
inhibitors of non-lysosomal glucocerebrosidase (GBA2), which displayed 100,000 fold selectivity for 42 
GBA2 over GBA[55]. GBA2 is involved in the degradation of glucosylceramide and is a potential 43 
therapeutic target in Niemann-Pick type C disease[56]. FluoPol-ABPP may provide a general strategy 44 
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to identify inhibitors of retaining GHs, without the requirement for screening assays based on 1 
fluorogenic or chromogenic substrates.  2 
4.4. Glycosidase ABPP for biotechnology  3 
Although many early glycosidase ABPP studies were biomedical in focus, recent years have seen an 4 
increasing drive to employ ABPP techniques towards biotechnological applications (Figure 4c). One 5 
early study in this arena, by Hekmat and coworkers, showed the promise of ABPP for the profiling of 6 
bacterial secretomes for biomass degrading enzymes[19]. The authors used 2-deoxy-2-fluoro-7 
disaccharides to profile the secretome of Cellulomonas fimi for cellobiohydrolase and 8 
xylobiohydrolase activity. Coupling isotopically tagged and biotinylated versions of these probes to 9 
mass spectrometry, the authors quantified active enzymes under variable growth conditions and also 10 
identified a previously unknown xylanase[57]. Schröder et al. recently carried a similar analysis of E-11 
xylosidases and E-xylanases in Aspergillus niger secretomes using cyclophellitol-derived ABPs. The 12 
authors demonstrated by both fluorescent labeling and proteomic analyses that A. niger secreted 13 
distinct catabolic enzymes depending on the carbon source utilized during its growth[58]. 14 
A comprehensive ABPP study of biomass degradation carried out by Chauvigné-Hines et al. utilized a 15 
suite of glucose and cellobiose configured ABPs to study the Clostridium thermocellum secretome[44]. 16 
A wide range of ABP chemistries were used in this study, encompassing fluorosugar, bromoketone 17 
and quinone methide based probes. Impressively, the authors were able to identify a large subset of 18 
the C. thermocellum glycosidases involved in biomass breakdown, including many proteins of the 19 
macromolecular cellulosome complex. dŚĞƵƐĞŽĨƐƵĐŚ ‘ƐƵŝƚĞƐ ?ŽĨWƐŵĂǇƌĞƉƌĞƐĞŶƚĂƵƐĞĨƵůƐƚƌĂƚĞŐǇ20 
to overcome limitations inherent to each class of glycosidase ABP (see section 3).  21 
ABPP has also been used as a tool to study intestinal microbiota. Whidbey and coworkers recently 22 
used quinone methide generating E-glucuronidase ABPs for labeling of whole cells derived from 23 
mouse gut microbiomes[59]. The authors sorted labeled cells using fluorescence activated cell sorting 24 
(FACS) to produce both labeled and unlabeled subpopulations. The identities of the E-glucuronidase 25 
positive community members were subsequently revealed by 16S rRNA sequencing of 26 
subpopulations. E-glucuronidase active taxa were compared between hosts and under antibiotic 27 
treatment conditions, revealing distinct taxa active in different hosts. This is a powerful technique as 28 
it clearly links function to taxa without the need for genomic context.  29 
5. Future challenges for glycosidase ABPP  30 
Several decades after the development of the first mechanism-based glycosidase inhibitors, the field 31 
of activity-based glycosidase profiling is now reaching maturity, at least with respect to retaining 32 
glycosidases. The field has seen the development of several different warhead chemistries[10,14,36], 33 
as well probes tailored to react with specific retaining glycosidase families[10,17,49]. Our experience 34 
suggests that, in principle, any retaining glycosidase that employs the Koshland double displacement 35 
mechanism is amenable to ABP profiling. Whilst  ‘monosaccharide ? ABPs that target retaining exo-36 
glycosidases have been relatively well explored, profiling of retaining endo-glycosidases will require 37 
more complex ABPs structures to mimic the length and/or branching of their natural substrates. Given 38 
past and recent successes in the  glycosylation of fluoroglycoside[20,60], cyclophellitol-derived[58,61], 39 
and bromoketone[37] warheads, the general profiling of retaining endo-glycosidases appears to be 40 
within reach.  41 
In contrast to fluorophosphonate-type ABPs, which react with large numbers of serine hydrolases, the 42 
development of truly broad-spectrum retaining glycosidase ABPs has remained elusive. Removal of  43 
hydroxyls from an ABP scaffold, as was recently done for cyclophellitol-derived ABPs[62], yields 44 
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broader spectrum probes at a cost of markedly reduced potency. The use of multiple ABPs in 1 
multiplexed labeling experiments provides a possible strategy to circumvent this problem, which also 2 
offers an attractive bonus: the relative specificity rendered by the configuration of the probes 3 
translates to the specificity of the glycosidases that are labeled. Interrogation of e.g. a microbial 4 
secretome derived from biomass growth using a set of differently fluorescent glycosidase ABPs will 5 
ǇŝĞůĚĂ  ‘ŵƵůƚŝĐŽůŽƌĞĚ ? ĨŝŶŐĞƌƉƌŝŶƚof the possible glycosidases present. First forays in activity-based 6 
secretome profiling indicate the huge potential of glycosidase ABPs in the field of biotechnology, in 7 
addition to their more developed applications in biomedicine (inhibitor discovery, target engagement, 8 
diagnostics).  9 
The enzymatic mechanism of retaining glycosidases proceeds through a covalent enzyme-substrate 10 
intermediate, which has provided us with a fortuitous route towards the design of ABPs for this 11 
enzyme class. The extensive choice of probe chemistries now on offer for retaining glycosidases may 12 
present a daunting choice for researchers when selecting suitable ABPs for their studies. In our 13 
experience, cyclophellitol-derived ABPs are excellent first choice molecules for a wide range of in vitro, 14 
in cellulo and even in vivo applications. Cyclophellitol-derived ABPs typically adopt a ground state 4H3 15 
conformation that mimics the substrate transition state conformation for many glycosidases[48,58], 16 
meaning these probes often label with high potency, producing stable enzyme-cyclitol linkages 17 
suitable for various downstream analyses. Conversely, glycosidases that do not employ a 4H3 transition 18 
state conformation can be less reactive towards cyclophellitol-derived ABPs, as has recently been 19 
observed with GH11 E-xylanases (proposed to utilize a 2,5B transition state conformation[58]). In such 20 
cases, fluorosugars may be more suitable, as they more closely resemble natural substrate 21 
glycones[63]. For E-glucosidase, E-galactosidase, and related glycosidase classes, fluorosugar 22 
inhibitors typically form stable, long-lived intermediates well suited for ABP derivation. However, in 23 
some cases (notably with 2-deoxy-2-fluoro-D-glycosides and D-glycosidases), fluorosugar inhibitors 24 
are too rapidly turned over to be of use as probes. In such cases, combining fluoro- and carbasugar 25 
chemistries may help to stabilize the covalent enzyme-probe intermediate[23,24]. Alternatively, 26 
controlled turnover of fluorosugar inhibitors can be useful in time-dependent labeling applications, 27 
where reactivation of the enzyme is desired.   28 
In contrast to the wide range of ABPs available for typical retaining glycosidases, ABPs that efficiently 29 
and specifically label other glycoprocessing enzymes (atypical retaining glycosidases utilizing oxidative 30 
or substrate assisted mechanisms, inverting glycosidases, glycosyl transferases, polysaccharde lyases, 31 
oxygenases) remain elusive. Opening up these enzyme classes to ABPP has huge potential in both the 32 
biomedical and biotechnological arenas. Some progress towards ABPP of inverting glycosidases has 33 
been made with photo-affinity and quinone methide based probes, which are indiscriminate with 34 
respect to catalytic mechanism[41]. However, these labeling chemistries also suffer from a relative 35 
lack of efficiency and selectivity. We postulate that widespread adoption of ABPP for other 36 
glycoprocessing enzyme classes will only take place after effective irreversible enzyme active site 37 
binders are identified. The development of such molecules will require the efforts of high-level 38 
synthetic chemistry, coupled to computation and structural analysis of the reaction mechanisms and 39 
conformational itineraries utilized by these diverse enzyme classes.  40 
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 1 
Figure 1 Conceptual basis for ABP design. a The three fundamental components of an ABP. Note - 2 
some probes may lack a specificity motif, endowing them with broad spectrum activity against a range 3 
of enzymes e.g. serine hydrolase probes in Ref [3]. b Examples of ABPs designed to target various 4 
enzymes and enzyme classes. Colors correspond to ABP components as outlined in a. 5 
 6 
 7 
11 
 
 1 
Figure 2 Mechanisms of glycoside hydrolases and inhibitor action. a Mechanism of glycoside cleavage 2 
by inverting (one step) and retaining (two step) glycosidases b Fluorosugar inhibitors (2-deoxy-2-3 
fluoro-glycoside shown here) are processed by retaining glycosidases, but the slow deglycosylation 4 
step results in inactivated enzyme. c Sugar epoxides (e.g. CBE or cyclophellitol) are attacked at their 5 
pseudo-anomeric center by glycosidase catalytic nucleophiles, leading to irreversible alkylation of this 6 
residue. d Haloketone glycosides employ an electrophilic trap, which can irreversibly alkylate residues 7 
within an enzyme active site (alkylation of the catalytic acid/base residue is shown here). e Photoactive 8 
glycoside AfBPs form a reactive species upon photoexcitation (carbene formation from a diazirine 9 
shown here), which reacts with neighboring protein residues to form irreversible linkages. f Quinone 10 
methide glycosides release a reactive species when cleaved, which can irreversibly alkylate a nearby 11 
nucleophilic protein residue. 12 
12 
 
 1 
Figure 3 Conformational aspects of glycosidase ABP reactivity. a Conformational itineraries for half-2 
reactions (initial substrate binding to covalent intermediate formation) catalyzed by typical retaining 3 
D- and E- glucosidases. Both classes of enzymes proceed via a 4H3 transition state. b Conformational 4 
FEL for a cyclophellitol derived molecule (carba-cyclophellitol, R=CH2), showing a ground state 5 
conformation centered around 4H3. Cyclophellitol-derived ABPs are transition state mimics and potent 6 
inactivators of many retaining classes of retaining glycosidases. c Conformational FEL for D-7 
cyclophellitol cyclosulfate, showing a ground state conformation centered around 4C1. This 8 
conformation matches the typical D-glucosidase Michaelis complex conformation, rendering D-9 
cyclophellitol cyclosulfates potent selective inactivators of D-glucosidases.  10 
13 
 
 1 
Figure 4 Recent applications of Glycosidase ABPs for protein profiling. a Glycosidase specific probes 2 
can detect the absence of enzyme expression in genetic diseases. ABPs have also been used to detect 3 
the presence of glycosidase activity in tissue samples, as well as in whole organisms in vivo. b FluoPol 4 
assays for glycosidases involves the use of a fluorescent ABP, the enzyme of interest and compound 5 
libraries. Glycosidase labeling by the ABP results in a maintenance of fluorescence polarization, whilst 6 
competition by inhibitors results in a loss of polarization. The specificity of identified hits can then be 7 
interrogated through SDS-PAGE and other downstream assays. c Glycosidase ABPs can be used to 8 
profile biomass degrading enzymes and microbiota community members. Active enzymes present in 9 
microbial secretomes can be profiled by SDS-PAGE and active proteins identified using pulldowns and 10 
mass spectrometry. Whole cells can be labeled and sorted with the use of FACS. Communities of either 11 
active or inactive populations can then be investigated through sequence-based identification of 12 
microbial taxa.  13 
 14 
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